Breaking News

Moderna's Q1 profit soars as Covid-19 vaccine sales boost revenue

May 5, 2022

Moderna reported a 200 per cent surge in its first-quarter net profit, as the US pharmaceutical and biotech company's revenue rose on the back of its Covid-19 vaccine.

The Massachusetts-based company's net income climbed to about $3.7 billion in the three months to the end of March, it said in a statement on Tuesday.

Moderna's shares were trading about 1 per cent lower at $145.1 a share at 8.11pm UAE time on Wednesday.

Total revenue reached $6.1bn in the January-March period, a yearly increase of more than 213 per cent. The amount included $5.9bn from sales of the company's Covid-19 vaccine, compared with $1.7bn in the first quarter of 2021.

Moderna said the prevailing market dynamics will result in Covid-19 vaccine sales “slightly larger in the second half of 2022 than in the first half”.

“The Moderna team delivered a strong first-quarter performance and I am thankful for the progress our team continues to make as we advance our pipeline of mRNA medicines. Today, we are reiterating our signed advanced purchase agreements for 2022 of $21bn,” Stephane Bancel, chief executive of Moderna, said.

While traditional vaccines give the body a weakened or inactive virus to cause the production of antibodies, mRNA vaccines make cells produce a protein that starts an immune response.

The company spent almost $554m on research and development in the first quarter, an increase of more than 38 per cent on an annual basis, mainly due to increases in “personnel-related costs, clinical trial expenses, technology and facility-related costs, and consulting and outside services”, it said.

Full-year R&D expenses are expected to be approximately $4bn.

Last month, Moderna also submitted a request for an emergency use authorisation in the US for its Covid-19 vaccine for babies aged 6 months to children under 6. Very young children are the only group that are yet to be eligible for the Covid-19 vaccine in the US and in most countries — a source of concern for some parents.

In the current quarter ending on June 30, Moderna expects to have four programmes in late-stage phase three studies, including an Omicron-containing bivalent Covid booster candidate, Mr Bancel said.

“Beginning in the fall of 2022, our robust phase-three pipeline could lead to three respiratory commercial launches over the next two to three years … mRNA has changed the future of medicine and I look forward to continuing our impact on human health. This is just the beginning,” he added.

Cash and cash equivalents stood at $19.3bn as of March 31. Meanwhile, the net cash provided by operating activities was $2.8bn for the three months ended on March 31, compared with $3bn for the same period in 2021.

Moderna's earnings per share increased 202 per cent on an annual basis to $8.6 in the first quarter.

The company expects total capital investments for 2022 to hover in the range of $600m to $800m.

Moderna, which did not conduct share repurchases before the fourth quarter of last year, said it spent $623m in the last quarter for repurchases of common stock.

In the last two quarters, the company has repurchased about 7 million shares, reducing the number of common shares outstanding from 405 million to nearly 400 million.

In February, the company approved a share repurchase programme for $3bn to return excess capital to shareholders. The previous programme of $1bn, announced in August, was fully utilised as of January 31, the company said.


Top News


Fakeeh University Hospital to digitalise...
May 24, 2022
Julphar announces Dh418.6 million in net...
May 18, 2022
Julphar records first-quarter profit on ...
May 17, 2022